ASH 2023 | Odronextamab in CAR-T relapsed diffuse large B-cell lymphoma
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the results of the ELM-2 study (NCT03888105), which tested odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who had previously progressed on CAR-T therapies. Odronextamab is known to be effective in treating DLBCL, however, with such high risks of relapse in this disease, testing in this specific cohort was necessary. The overall and complete response rates were encouraging for such a high-risk population, with high probabilities of response retention. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
